Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | TDO2 | P48775 | 1/20 | 0.55 |
| ▸ | CCKBR | P32239 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247406 | 1.00 | IDO1 (0.55) | IDO1TDO2CCKBRALPIPKM | |
| SCHEMBL5217962 | 0.87 | IDO1 (0.46) | IDO1TDO2CCKBRAKT1TACR1 | |
| SCHEMBL14619153 | 0.86 | IDO1 (0.46) | IDO1TDO2CCKBRALPIPKM | |
| SCHEMBL2605810 | 0.85 | CCKBR (0.41) | IDO1TDO2CCKBRAKT1TACR1 | |
| SCHEMBL12680063 | 0.85 | IDO1 (0.39) | IDO1TDO2CCKBRAKT1TACR1 | |
| SCHEMBL13188042 | 0.83 | IDO1 (0.41) | IDO1TDO2AKT1TACR1 | |
| SCHEMBL6860568 | 0.83 | IDO1 (0.41) | IDO1TDO2AKT1TACR1 | |
| SCHEMBL14129011 | 0.81 | AKT1 (0.37) | IDO1TDO2AKT1TACR1 | |
| SCHEMBL14185276 | 0.81 | NOD1 (0.42) | IDO1TDO2PTGS1AKT1TACR1 | |
| SCHEMBL10181262 | 0.81 | IDO1 (0.40) | IDO1TDO2CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | SIXTH STREET LENDING PARTNERS | 2024-03-07 | — | — | US | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | claimed |
| EP-4105224-A1 | LONG-ACTING COMPSTATIN ANALOGS AND USES THEREOF | Apellis Pharmaceuticals, Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-105582523-B | Compstatin and analogs thereof for ocular disorders | 阿佩利斯制药公司 | 2022-04-15 | — | — | CN | claimed |
| EP-2707384-B1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | claimed |
| CN-107050422-B | Cell-reactive, long-acting or targeted compstatin analogs and uses thereof | 阿佩利斯制药公司 | 2021-11-09 | — | — | CN | claimed |
| US-20180118785-A1 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-03 | — | — | US | claimed |
| US-20170190741-A9 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-07-06 | — | — | US | claimed |
| EP-2311480-B1 | Compstatin analogs with improved activity | UNIV PENNSYLVANIA (US) | 2013-06-26 | — | — | EP | claimed |
| EP-1549333-B1 | COMPSTATIN ANALOGUES WITH IMPROVED ACTIVITY | UNIV PENNSYLVANIA (US) | 2011-09-21 | — | — | EP | claimed |
| US-7989589-B2 | Compstatin analogs with improved activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-02 | — | — | US | claimed |
| EP-2311480-A1 | Compstatin analogs with improved activity | The Trustees of The University of Pennsylvania (US) | 2011-04-20 | — | — | EP | claimed |
| EP-2311479-A1 | Compstatin analogs with improved activity | The Trustees of The University of Pennsylvania (US) | 2011-04-20 | — | — | EP | claimed |
| JP-4614222-B2 | — | — | 2011-01-19 | — | — | JP | claimed |
| US-20100222550-A1 | Compstatin analogs with improved activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-02 | — | — | US | claimed |
| EP-1549333-A4 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY | UNIV PENNSYLVANIA (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1549333-A1 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY | The Trustees of The University of Pennsylvania (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004026328-A1 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2004-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | C3AR1, C5AR1, SERPINC1 | IDO1 1531/4885TDO2 4510/4885CCKBR 550/4885 |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | C3AR1, C5AR1, SERPINC1 | IDO1 1531/4885TDO2 4510/4885CCKBR 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.